The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).
Price action
With a market capitalization of Rs. 92,246.50 Crores on Thursday, the shares of Zydus Lifesciences Ltd jumped upto 6.8 percent after making a high of Rs. 947.95 compared to its previous closing price of Rs. 887.55.
What Happened
Zydus Lifesciences engaged in developing, manufacturing, and marketing a wide range of pharmaceuticals has received final approval from the USFDA to manufacture Dasatinib Tablets in various strengths (20 mg to 140 mg). These tablets are used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
The tablets will be produced at Zydus’ SEZ facility in Ahmedabad, and this Dasatinib tablet had annual sales of $1.8 billion in the US as of January 2025. This approval brings Zydus’ total number of approvals to 415, with 483 ANDA filings since FY 2003-04.
About the company
Zydus Lifesciences Ltd is a leading global healthcare company based in India, primarily focused on developing, manufacturing, and marketing a wide range of pharmaceuticals, including generics, active pharmaceutical ingredients (APIs), and consumer wellness products.
Key Highlights (Q3 FY25)
India’s formulation business grew faster than the market, driven by strong chronic outperformance with secondary sales growth of 8 percent according to IQVIA. The Consumer Wellness business grew in double digits, supported by robust volume growth of 4.8 percent despite a muted demand scenario in the industry.
The U.S. formulations business continued its upward trajectory, with impressive year-on-year growth driven by volume expansion and new launches over the past 12 months. The international markets business grew in double digits, supported by healthy demand across various markets.
Business-wise sales Breakup
The company generates 29 percent of its product sales from India Formulations, amounting to Rs. 1489.3 crore, the Consumer Wellness segment contributes 9 percent which is 461.1 crore, U.S market generates 47 percent totaling Rs. 2407.9 crore, and international Formulations contribute 11 percent of Rs. 563.6 crores, API segment 3 percent which is Rs. 153.7 crores, and lastly, alliances contribute 1 percent amounting to Rs.51.2 crores of the total sales of 5,123.5 crores.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
